Prevymis (letermovir) / Merck (MSD), AiCuris - LARVOL DELTA

The Impact of Letermovir on Tacrolimus Pharmacokinetics and Clinical Outcomes Among Allogeneic Hematopoietic Cell Transplant Recipients (HOPA 2026) - "Letermovir was routinely initiated on D+15, while tacrolimus was initiated on D-3 for traditional aGVHD prophylaxis and D+5 for post-transplant cyclophosphamide. This study demonstrated a significant tacrolimus-letermovir DDI resulting in lower weight-adjusted tacrolimus doses. However, the study suggests the DDI is not likely clinically significant, and empiric tacrolimus dose adjustments are not required with letermovir initiation."

Clinical • Clinical data • PK/PD data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation

Letermovir for CMV prophylaxis after haploidentical HSCT: a prospective study of direct and indirect effects. (PubMed, Int J Antimicrob Agents) - P | "High-risk patients warrant enhanced immunological monitoring and extended letermovir prophylaxis."

Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Infectious Disease • Transplantation • CD4 • CD8 • NCAM1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2027 ➔ Feb 2030 | Trial primary completion date: Jun 2027 ➔ Feb 2030

Enrollment open • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • HLA-B • HLA-C • HLA-DPB1 • HLA-DQB1 • HLA-DRB1

Letermovir-Associated Post-Transplant Lymphoproliferative Disorder (USCAP 2026) - "While our cohort is small, all of the lesions diagnosed in stem cell transplant patients may be classified as nondestructive lesions per International Consensus Classification (ICC) 2022 and hyperplasias arising in immune deficiency/dysregulation per World Health Organization classification 2022, which, per ICC, represent only 5% of PTLD. This may be a trend warranting investigation with larger cohorts. Additionally, the interplay between CMV status and prophylaxis and Epstein-Barr virus in the setting of immunodeficiency remains fertile ground for future investigation."

Post-transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Hematological Malignancies • Lymphoma • Multiple Myeloma • Transplantation

Comprehensive management of hematopoietic stem cell transplantation complications: from infection prevention to immune microenvironment reconstruction. (PubMed, Front Immunol) - "It highlights the importance of optimizing conditioning regimens to reduce infection risk and discusses the role of novel antiviral agents like letermovir in transforming infection control. For GVHD, the pathogenesis involving effector and regulatory T-cell imbalances is analyzed, together with prevention strategies such as post-transplant cyclophosphamide with antithymocyte globulin and TCRαβ/CD19 depletion. Ruxolitinib is emphasized for steroid-refractory GVHD, and gut microbiota modulation is noted as a promising intervention. For VOD/SOS, early biomarker detection and defibrotide treatment are critical. The review also explores the impact of immune reconstitution on infection control, GVHD development, and relapse, and examines how emerging approaches, including single-cell sequencing, microbiome analysis, and artificial intelligence, can be applied in building whole-course risk management models. Future directions include developing intelligent platforms and..."

Journal • Review • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

PREVIOUS ANTITHYMOCYTE-BASED IMMUNOSUPPRESSIVE THERAPY INCREASED THE RISK OF VIRUS REACTIVATION IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA (EBMT 2026) - "No letermovir prophylaxis for cytomegavirus (CMV) reactivation was used during the study period... In conclusion, salvage haplo-HCT led to an increased risk of virus reactivation, especially EBV and ADV reactivation. However, comparable survival rates to those of upfront haplo-HCT were achieved. Preliminary subgroup analysis suggested that, for patients who failed to respond to IST, timely consideration of haplo-HCT could be beneficial."

Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation

TREOSULFAN-FLUDARABINE AS A REDUCED INTENSITY CONDITIONING ALTERNATIVE TO BUSULFAN-FLUDARABINE FOR ADULT ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE-CENTER, EARLY REAL-LIFE CLINICAL AND ECONOMICAL COMPARATIVE OUTCOMES (EBMT 2026) - " We retrospectively reviewed all allo-HCTs performed between 2021 and 2025 using FT10 or FB2 conditioning, both combined with anti-lymphocyte globulin ((ATG) Thymoglobulin 5 mg/kg or Grafalon 30 mg/kg), for adults with AML or MDS. Transplant practices were identical across the study period: peripheral blood stem cell grafts, ciclosporine + methotrexate for GVHD prophylaxis, letermovir prophylaxis, and unchanged center-level procedures and teams... Despite being used in a substantially higher-risk population, FT10 achieved early post-transplant outcomes comparable to FB2, with a lower burden of early unplanned healthcare costs. These findings support the feasibility and cost effectiveness of FT10 as a reduced-toxicity RIC option for AML/MDS."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Hepatology • Immunology • Transplantation

INCIDENCE AND RISK FACTORS FOR POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN A MULTICENTER COHORT (EBMT 2026) - "GVHD prophylaxis consisted of PTCy plus mycophenolate mofetil and a calcineurin inhibitor, using peripheral blood or bone marrow as the graft source...Management included thrombopoietin receptor agonists (TPO-Ras) (n=21), TPO-Ras plus filgrastim and erythropoietin (n=7), filgrastim alone (n=13), or transfusional support; seven patients required second-line therapy (CD34⁺ boost n=3, change of TPO-Ras n=3, second transplant n=1)...Letermovir prophylaxis was used in 56/427 seropositive receptors... In this multicenter cohort of allo-HSCT recipients receiving PTCy-based GVHD prophylaxis, the incidence of PGF was not higher than that reported in non-PTCy platforms. Bone marrow graft source, CMV reactivation within 6 months, and donor-specific anti-HLA antibodies were the main independent risk factors for PGF. These findings support optimization of graft quality and intensified CMV monitoring and prophylaxis strategies in patients receiving PTCy."

Clinical • Post-transplantation • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Transplantation

ΑΒT/CD19 DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE SALVAGE THERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY PATIENTS WITH HODGKIN LYMPHOMA (EBMT 2026) - "Conditioning consisted of ATG 1,5 mg/kg from day -13 to day -10, Treosulfan 12gr/sqm from -9 to –7, Fludarabine 30mg/sqm from -6 to -2 and Thiotepa 5mg/Kg on days -5 and -4...One patient died because of recurrent CMV reactivation in patient with an unfavorable sierology R POS/D NEG in pre letermovir era and the other one due to GVHD post Donor lymphocyte Infusion...CMV reactivation occurred, in 5 patients, with one experiencing organ disease, and EBV reactivation in three, that completely responded to 2 cycles of Rituximab... Allogenic transplantation with ab T cell depletion is an effective and safe approach in relapsed/refractory Hodgkin lymphoma heavily pretreated, with a rapid donor hematopoietic engraftment and very promising outcome, with a very low transplant related mortality in patients heavily pretreated before HSCT."

Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Transplantation • CD34 • NCAM1

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR MALIGNANT AND NON-MALIGNANT HEMATOLOGIC DISORDERS: A REAL-WORLD EXPERIENCE FROM QATAR (EBMT 2026) - "TBI-based conditioning with fludarabine 160 mg/m² and TBI 1200 cGy were administered to 30 patients (69.8%), whereas 13 patients (30.2%) received non-TBI conditioning...Three patients (7%) had grade 3 CRS and required tocilizumab. Clinically significant CMV infection was significantly higher in patients who did not receive letermovir prophylaxis (92%) than in those who did (11.6%). One patient developed VOD that was treated with defibrotide... Haplo-HCT with PTCy leads to excellent survival for patients who lack HLA-matched donors or access to an unrelated donor. Our results revealed universal engraftment, higher rates of disease-free survival and an improved graft-versus-host disease-free-relapse-free survival. Finally, in our cohort, both chemo and radiotherapy-based conditioning haploidentical cell transplantation resulted in low rates of relapse, non-relapse mortality and chronic GVHD."

Clinical • Post-transplantation • Real-world • Real-world evidence • Acute Graft versus Host Disease • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Transplantation

LOW-LEVEL PRETRANSPLANT CMV DNAEMIA IS ALREADY A RISK FACTOR FOR POSTTRANSPLANT CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (EBMT 2026) - "Background: Clinically-significant CMV infections (csCMVi) still occur in allogeneic hematopoietic cell transplant recipients (allo-HCTr), even on letermovir prophylaxis... Whereas pre-HCT CMV DNAemia was strongly associated with increased post-HCT csCMVi incidence, the magnitude of the VL is not associated with an increased risk. This suggests that any DT pre-HCT CMV DNAemia may represent an activity of CMV reservoir and could be considered as a relevant risk factor for csCMVi, regardless of the VL."

Clinical • Post-transplantation • Pre-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

SINGLE-CENTER RETROSPECTIVE CLINICAL STUDY ON THE CONDITIONING REGIMEN OF DECITABINE, THIOTEPA, BUSULFAN, AND FLUDARABINE (DTBF) COMBINED WITH ATG/PTCY FOR ALTERNATIVE DONOR TRANSPLANTATION IN MYELODYSPLASTIC NEOPLASMS (EBMT 2026) - "Thiotepa has been demonstrated favorable safety and efficacy in conditioning regimens for transplantation.However, no research data have been reported yet on the DTBF conditioning regimen combined with anti-thymocyte globulin (ATG)/post-transplantation cyclophosphamide (PTCy) in alternative donor HSCT for adult MDS...The GVHD prophylaxis regimen was based on ATG (7.5 mg/kg) combined with low-dose PTCy (29mg/kg), supplemented with cyclosporine, mycophenolate mofetil, and short-course methotrexate...All patients received letermovir for cytomegalovirus (CMV) infection prophylaxis... The preliminary data indicate that the DTBF + ATG/PTCy conditioning regimen demonstrates favorable efficacy and safety for alternative donor-HSCT in adult MDS patients.Future evaluations will involve expanding the patient cohort and extending the follow - up periods."

Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Mucositis • Myelodysplastic Syndrome • Stomatitis • Transplantation

HUMAN HERPES VIRUS 6 INFECTION IN ALLOGENEIC STEM CELL TRANSPLANTATION RECEIVING POST-TRASPLANT CYCLOPHOSPHAMIDE (EBMT 2026) - "Clinical Trial Registry: Not Applicable. Epidemiology of HHV6 infection is changing in allo-HCT due to the new approaches in GvHD prophylaxis (PTCy regimen) and Letermovir prophylaxis for CMV infection (excellent control on CMV infection). Gastrointestinal infection is the most frequent organ presentation with a good response to antiviral treatment."

CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Transplantation

EBV REACTIVATION AND PTLD IN THE LETERMOVIR ERA: BEYOND ANTIVIRAL PROPHYLAXIS (EBMT 2026) - "IIn this real-world allo-HSCT cohort, EBV-R and PTLD increased over time and were associated with ATG, PTCy, and donor type. Day-30 immune reconstitution was a key risk factor. EBV-R/PTLD were marked by poor T-cell recovery, increased NK- and B-cells, and a protective effect from higher early CD4⁺ and activated NK/T-cells."

Aplastic Anemia • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • CD4 • CD8

CYTOMEGALOVIRUS REACTIVATION IN A SINGLE CENTER PAEDIATRIC COHORT UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION AND USE OF LETERMOVIR (EBMT 2026) - "The collected variables included: age, donor/recipient CMV serology, prophylaxis with letermovir, myeloablative or reduced-intensity conditioning, administration of serotherapy and donor type (HLA- identical sibling [MSD], haploidentical with post-transplant cyclophosphamide, other related donors [MMFD] and matched unrelated donor [MUD]. CMV reactivation is a common complication following HSCT. Letermovir could be effective for prophylaxis in seropositive paediatric patients without significant toxicity. In our series, patients who received serotherapy reactivated CMV more frequently."

Clinical • Aplastic Anemia • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Gastrointestinal Disorder • Pediatrics • Transplantation

THE IMPACT OF CMV-SEROPOSITIVITY ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF LETERMOVIR IN AML AND MDS PATIENTS (EBMT 2026) - "Our findings suggest that, even in the letermovir era, the CMV serostatus may still affect RFS. Furthermore, we found no evidence that prophylaxis with letermovir or CMV infection are relevant risk factors for relapse in our large cohort of AML and MDS patients. However, further studies are needed to confirm these findings and to evaluate the possible impact of donor CMV serostatus and the underlying mechanisms."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Transplantation • CD4 • CD8

OUTCOME OF CMV PNEUMONIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF MODERN TRANSPLANTATION AND CMV PREVENTION PRACTICES (EBMT 2026) - "Background: The incidence of early cytomegalovirus (CMV) pneumonia has decreased significantly with the introduction of routine PCR surveillance and next letermovir prophylaxis in allogeneic hematopoietic cell transplantation (HCT) recipients; however, late episodes of the CMV disease still occur and contribute to transplant-related mortality... CMV pneumonia incidence and mortality have continued to decline in the modern era, although late cases remain clinically relevant. The prognosis for patients requiring mechanical ventilation at the time of diagnosis remains poor, despite the improvement of transplant and supportive care techniques. The addition of IVIG or CMV-specific immunoglobulin to antiviral therapy did not show a clear survival benefit in this cohort, suggesting limited evidence to support their routine use."

Cytomegalovirus Infection • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Transplantation

EARLY ADMINISTRATION OF LETERMOVIR PROPHYLAXIS POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IS ASSOCIATED WITH DELAYED ENGRAFTMENT (EBMT 2026) - "Patient characteristics were similar between the 2 periods except for higher rates in the post-letermovir period of peripheral blood versus bone marrow stem cells for HCT sources, and of cyclophosphamide-based regimens for GvHD prophylaxis. In our cohort, engraftment is slightly but significantly delayed in allo-HCTR+ receiving letermovir compared to the pre-letermovir period, despite the reduction in post-HCT CMV reactivation incidence and improved survival. In the literature, few studies report on engraftment but 5/9 studies also find delayed engraftment in letermovir-receiving patients. This effect is independent of other tested covariables and could be due to the drug itself or virus-mediated."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation

REAL-WORLD UTILIZATION AND EFFICACY OF BIOEQUIVALENT GENERIC LETERMOVIR PROPHYLAXIS IN ALLOGENEIC HSCT RECIPIENTS: PEDIATRIC SUBGROUP ANALYSIS FROM DEFENDER STUDY (EBMT 2026) - "Pre-emptive therapy was required in 13 patients (12.87%), primarily ganciclovir (10.89%) and cidofovir (1.98%). Letermovir prophylaxis demonstrated acceptable efficacy and excellent tolerability in pediatric allo-HSCT recipients, with low adverse event rates and high completion rates. Real-world data support letermovir use in pediatric transplant populations and highlight the need for individualized dosing strategies."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Pediatrics • Sickle Cell Disease

LATE CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HSCT PERSISTS IN THE ERA OF LETERMOVIR PROPHYLAXIS – A SINGLE-CENTRE REAL WORLD STUDY (EBMT 2026) - "413/480 (86%) received reduced intensity conditioning regimens, and 397/480 were T-cell deplete (Campath 226/480; 47.1%, ATG 93/480; 19.4%, PTCy 79/480; 16.5%)...20/27 (74.1%) of the post-letermovir reactivators required treatment with an additional anti-viral agent (p=0.52); 3 required admission for treatment with foscarnet (2 having been pre-treated with valganciclovir)... CMV reactivation remains a frequent issue post-allo-HSCT. Letermovir defers the median onset of csCMV to post-D100, but does not reduce the need for further anti-viral treatment."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Ophthalmology • Pneumonia • Retinal Disorders

LETERMOVIR PRIMARY PROPHYLAXIS IS A PROTECTIVE FACTOR FOR SURVIVAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS. DATA FROM THE FIRST PROSPECTIVE MULTICENTER STUDY IN LATIN AMERICA (EBMT 2026) - "CMV seronegative donors, alternative donors, post-transplant Cyclophosphamide administration and T-cell depletion were compared in PET vs. LET groups: 12.43% vs. 30.73% (p<0.001), 56.94% vs. 87.32% (p<0.001), 51.73% vs. 80.98% (p<0.001), and 12.14% vs. 15.61% (p=0.24), respectively. Our cohort largely comprised patients at high risk of developing cs-CMVi and CMV-d. Notwithstanding that, LET primary prophylaxis effectively prevented CMV-related complications, reduced rehospitalizations and was a protective factor for survival. These data support the use of this antiviral for primary prophylaxis in seropositive aHCT patients in Latin American countries."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation

CMV AND EBV REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (EBMT 2026) - "Regarding GVHD prophylaxis, anti-thymocyte globulin (ATG) was used in 83.8% (n=62) of patients, and post-transplant cyclophosphamide (PTCy) was used in 17.6% (n=13). For pre-transplant antiviral prophylaxis, ganciclovir was administered to 89.2% (n=66) of patients and foscarnet to 21.6% (n=16)... In elderly haplo-HCT recipients, EBV reactivation correlates with inferior survival, whereas early CMV reactivation predicts disease relapse without compromising survival. Letermovir prophylaxis effectively mitigates CMV risk but is independently associated with increased EBV reactivation, presenting a clinical trade-off. These findings highlight the distinct prognostic implications of viral kinetics and underscore the necessity for balanced prophylactic strategies and vigilant monitoring in this vulnerable population."

Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

IMPACT OF LETERMOVIR PROPHYLAXIS ON CYTOMEGALOVIRUS EVENTS AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AML AND MDS (EBMT 2026) - " We conducted a single-center retrospective study of adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who underwent first allo-HSCT with uniform fludarabine/busulfan-based conditioning between January 2016 and September 2024. Letermovir prophylaxis fundamentally reshapes the post-transplant CMV landscape, uncoupling ECMVR from routine clinical observation. Although letermovir use was associated with higher unadjusted relapse incidence, this association disappeared after accounting for ECMVR and transplant-related covariates, while ECMVR itself remained independently protective against relapse. These data suggest that letermovir does not promote relapse but rather may obscure a CMV-associated immune signal linked to graft-versus-leukemia effects."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation

CURRENT TRENDS IN THE MANAGEMENT OF CYTOMEGALOVIRUS IN CELL THERAPIES RECIPIENTS IN SPAIN: RESULTS OF THE 2025 GETH-TC SURVEY (EBMT 2026) - " A structured online survey addressing 5 domains—use of letermovir (LMV), use of maribavir (MBV), advanced diagnostic tools, management of CAR-T/BITE recipients, and implementation of ECIL-10 recommendations—was distributed in May 2025 to adult and paediatric hematologists within the GETH-TC...Among recipients receiving post-transplant cyclophosphamide, 50% prescribed LMV only in the presence of additional risk factors... The 2025 GETH-TC survey demonstrates widespread adoption of modern CMV prevention and treatment strategies in Spain, including universal LMV use for primary prophylaxis and broad extension beyond day +100. MBV is increasingly integrated into the management of refractory or resistant CMV. Diagnostic practices are also evolving, with expanded use of resistance testing and immune reconstitution assessment."

Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology

COMPARATIVE ANALYSIS OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL VS MATCHED SIBLING DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "GVHD prophylaxis consisted of cyclosporine plus methotrexate for MSD transplants, and post-transplant cyclophosphamide on days +3/+4 followed by cyclosporine and mycophenolate for haploidentical HSCT...No patient received letermovir prophylaxis, as it only became available in Mexico after 2025... CMV reactivation was significantly more frequent after haploidentical transplantation, although the timing of reactivation and CMV-related clinical presentation were similar across donor types. Overall survival did not differ according to donor type; however, CMV reactivation was associated with inferior long-term survival. These findings suggest that CMV reactivation represents a clinically relevant event influencing outcomes after allogeneic hematopoietic stem cell transplantation, beyond donor type alone"

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • Transplantation